Moderna fully enrolls phase 3 trial for COVID-19 vaccine candidate, with heavy emphasis on traditionally under-represented communities

Oct 22, 2020 - 02:45 PM
COVID19 Web Sized

Moderna Inc., today announced the completion of enrollment for its COVID-19 vaccine phase 3 trial.

The drug maker said that it has confirmed 30,000 participants for an efficacy study of mRNA-1273. Moderna and the National Institute of Allergy and Infectious Diseases developed the candidate, which generated a strong immune response in older adults during its phase 1 clinical trial.

Communities that have historically been under-represented in clinical research and are disproportionately impacted by COVID-19 have significant representation among the trial enrollees. Moderna said the study includes more than 11,000 participants from communities of color, representing 37% of the study population and similar to the diversity of the U.S. at large. This includes more than 6,000 participants who identify as Hispanic or Latinx, and more than 3,000 participants who identify as Black or African American.

Related News Articles

Headline
CDC issues reminder on ending of the emergency authorization for COVID-19 in vitro diagnostics tests
The Centers for Disease Control and Prevention issued a reminder Oct. 14 that the declaration supporting the emergency use of COVID-19 in vitro diagnostics…
Headline
HHS seeks feedback on immunization categories in executive order on childhood vaccine schedule
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
CDC reports increase in kindergarten vaccine exemptions
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
Study finds COVID-19 can reactivate dormant viruses 
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
HHS to end emergency authorization for COVID-19 drugs, medical devices 
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
CMS Administrator Oz and Deputy Administrator Brillman discuss agency’s focus on innovation, reducing waste
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…